ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHU..SK................*JDIM360 (Ver 1.5 21 Nov 2005) - 2999001/01558615CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120071010W184deBibliographieenBibliographyfrBibliographieEP03751149.0200310212005053020051117enenen421874 P20021028US2007101020074120050803200531200708292007352007030120071010200741C07D 473/30 20060101AFI20040512BHEP C07D 473/34 20060101ALI20040512BHEP C07D 473/40 20060101ALI20040512BHEP C07D 239/48 20060101ALI20040512BHEP A61K 31/52 20060101ALI20040512BHEP A61P 3/04 20060101ALI20040512BHEP dePURINDERIVATE UND IHRE VERWENDUNG ALS LIGANDEN DES CANNABINOID REZEPTORSenPURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDSfrCOMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDESEP-A- 1 054 012US-A- 5 256 398PERTWEE G. R.: "Cannabinoid receptor ligands" EXP. OPIN. INVEST. DRUGS, vol. 9, no. 7, 2000, pages 1553-1571, XP009024282 cited in the applicationGRIFFITH, David A., Pfizer Global Research and DevelopmentEastern Point RoadGroton, CT 06340USPfizer Products Inc.02434221PC25033AEastern Point RoadGroton, CT 06340USMotion, Keith Robert00091141Pfizer Limited Patents Department Ramsgate RoadSandwich, Kent CT13 9NJGBATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEITLILUMCNLPTROSESISKTRAL20050530LT20050530LV20050530MK20050530IB200300461920031021enWO20040378232004050620041920050803200531